Wide mismatches in the sequences of primers and probes for Monkeypox

virus diagnostic assays

Fuqing Wu[1]*, Jeremiah Oghuan[1], Anna Gitter[1], Kristina D. Mena[1], Eric L. Brown[1]

1: The University of Texas Health Science Center at Houston, School of Public Health

Houston, Texas, USA 77030

* Correspondence to FW at fuqing.wu@uth.tmc.edu.

Abstract

The current monkeypox outbreak as a global health emergency now spreads into more than 90

counties. Rapid and accurate diagnosis of the infections is fundamental for the viral disease

containment. Here, we analyzed the primer and probe sequences in the CDC recommended

monkeypox virus (MPV) generic real-time PCR assay by aligning against 683 reported MPV

genomes worldwide. Sequence mismatches were found in more than 92% of genomes for the

MPV generic forward and reverse primers. We also evaluated the specificity of seven other real-

time PCR assays for MPV and orthopoxvirus (OPV) detection, and identified two assays

(MPV_F3L and OPV_F8L) with the highest matching score (>99.4%) to the global MPV

genome database. Genetic variations on the MPV genomes corresponding with the real-time

PCR primer and probe regions were further specified and used to indicate the temporal and

spatial emergence pattern of monkeypox disease. Our results show that the current MPV real-

time generic assay may be unsuitable to accurately detect MPV, highlighting the need to develop

new detection assays.

Keywords: Monkeypox virus, real-time PCR detection, sequence mismatch, genome alignment,

orthopoxvirus

Introduction

Our ability to detect emerging and reemerging infectious disease agents has never been as

important as it is today due to growing human populations and global travel. While the SARS-

CoV-2 is gradually becoming an endemic virus, the world is now seeing the re-emergence of

monkeypox virus (MPV). As of August 9, 2022, there are over 8,900 reported cases in the

United States and over 30,000 cases in 88 countries (1). The World Health Organization (WHO)

has declared a public health emergency of international concern on July 23, 2022 to respond the

rapid spread of MPV worldwide.

Monkeypox virus in the *Orthopoxvirus* (OPV) genus is a zoonotic double-stranded DNA virus

with a ~197 kbp genome (2,3). In 1970, monkeypox was first identified in humans in the

Democratic Republic of The Congo and Africa regions (4). Sporadic monkeypox cases were

reported outside of African (U.S. and Europe), however, the infections were either related with

international travel or exposure to animals imported from Africa (5,6). The first MPV case

associated with the present outbreak was reported on May 6 in the United Kingdom, followed by

cases in Spain, Portugal, and Canada (5,7). On May 18 cases were reported in Belgium, Italy; on

May 20 cases were reported in Australia, France, Germany, and the Netherlands; and on May 21

cases were reported in Switzerland and Israel (7). Such a wide outbreak within two weeks in

multiple counties across continents suggest that early non-reported transmission occurred before

May 2022 (8).

The polymerase-chain reaction (PCR) has been used in the detection and diagnosis of viral

infections such as SARS-CoV-2. On June 6, 2022 the Centers for Disease Control released a

real-time PCR test using generic primers and probe for the detection of MPV (9) based on

previous work conducted in 2010 describing the detection of a West African MPV strain and a

Congo Basin MPV strain (10). This MPV generic assay has been used to detect human MPV

infections and MPV present in wastewater samples (11,12). Several other real-time PCR assays

have also been reported for MPV or OPV detection in clinical samples (10,13–17). However, the

specificity and suitability of these generic primers and probe need to be carefully addressed

because most of the primers and probes (generic or lineage-specific) were based on sequenced

genomes obtained from MPV strains circulating more than a decade ago (2002 to 2009). Given

the fast evolution of viral species including DNA viruses (18,19) it is likely that mutations have

emerged in the oligos' targeting regions for current MPV strain. The present report analyzes the

oligos sequences used in conjunction with the current real-time MPV assays by aligning primer

sequences against 683 reported MPV complete genomes from GISAID as of August 5, 2022.

This analysis identified wide variations in the primer and probe sequences compared to the

genome of currently circulating MPV stains. Our results indicate that the current MPV real-time

generic assay may be unsuitable to accurately detect MPV and highlights the need to develop

new detection assays.

Materials and Methods

Data source. The MPV genomes were downloaded from GISAID (https://gisaid.org/). As of

August 5, 2022, 683 genomes with complete metadata were available, including 634 genomes

(samples) collected from May 19, 2022, to July 29, 2022. The rest 49 samples include 7 from

1962 to 2005, 11 samples in 2006, 12 samples in 2007, 7 samples in 2017, 8 samples in 2018, 2

samples in 2019, and 2 samples in 2021. Metadata includes accession ID, sample collection date,

sequence data submission date, and sampling location (Continent/country) associated with the

sequences. The monkeypox virus reference genome Zaire-96-I-16 was downloaded from NCBI

(NC_003310.1). MPV real-time assays (primers and probes) were from published studies

including MPV Generic assay (9), MPV_O2L (13), MPV_F3L (14), MPV_C3L (10),

MPV_G2R_WA (10), OPV_B2R (15), OPV_I7L (16), and OPV_F8L (17).

Sequence alignment. Genome sequences were downloaded as .fasta and imported into R

(version 4.1.3) as the MPV genome database for analysis. We aligned each of the oligo

(including forward primer, reverse primer, and probe) sequence to the database and computed

the percentage of matches and non-matches. For non-matches, sequence was extracted and

aligned by SnapGene software (https://www.snapgene.com/) to identify the specific nucleotides

that are distinct from sequence in the MPV oligos. If the 'mismatch' in the targeted genome

region is the correct degenerate codes, we treated it as 'match'. If the 'mismatch' is 'N' or

multiple 'N', we treated as 'non-match'. The major types of sequence variation (mutation) were

listed in Figure 1 and Figure 3A. In total, the original sequence and identified sequence variation

account for 99.4% ~ 100% of the total genomes for each of the MPV real-time assays. Four

genomes (0.6%) were excluded in the MPV_F3L assay (forward primer) because non-match was

found in the genome. These analyses were performed with customized R script.

Mutation-based epidemiological analysis. For each MPV assay, we identified the major

variation type(s) in the genome database and then assigned an identity as 'match' or 'mutation'

to each of the genome for the specific oligo. Two mutation types were found for the

MPV_G2R_WA assay and were labeled as 'Mutation1' and 'Mutation2', respectively. Merging

with the metadata associated with the genome, we summarized the number of genomes for

'match' and 'mutation' groups based on the sampling collection time (year), sampling location

(continent). We also sub-grouped the database by only selecting the year '2022' to compute the

percentages of 'mutation' in the current MPV outbreak.

Results

Generic MPV forward and reverse primers do not match the majority of reported genomes

We investigated whether forward and reverse primers and probe in the MPV generic assay match

to the reported MPV genomes. As of August 5, 683 complete genomes with metadata have been

uploaded in the GISAID. Of the 683 genomes, 634 (92.8%) were collected between May 19 and

July 29, 2022. We then aligned each of the MPV generic oligo sequences to the genome database.

Of the total 683 genomes, the MPV generic forward sequence (MPV-F, Figure 1A) had 100%

identity to sequences present in 28 (4%) of the genomes. A single-nucleotide mutation

A194165G (synonymous mutation, MPV-F-mu in Figure 1A) was found in 96% of the published

MPV genomes (Figure 1B), and 100% in the genomes published from May to July 2022. Similar

observations were also found in the generic reverse primer (MPV-R), which only matches 8% of

the genomes. A nonsynonymous substitution, C194233T in the reverse primer region, was

observed in 92% of the genomes (equivalent to 98.4% of genomes released from May to July

2022). In contrast, the probe sequence (MPV-P) is conserved and matches all of the genomes in

the database.

We further compared the MPV generic primers and probe with the sequenced samples in the U.S.

Of the total 58 genomes, the A194165G mutation in the forward primer region was observed in

all the U.S. genomes, and the C194233T mutation observed in the reverse primer region was

found in 93% of the U.S. genomes (Figure 1C), which are consistent with the results in Figure

1B. These results demonstrated that the CDC recommended forward and reverse primers

designed for MPV testing do not match the major genome sequences in recent samples with

MPV.

Figure 1. MPV generic forward and reverse primers do not match with the majority of

reported genomes. (A) Alignment of MPV generic forward primer, reverse primer, and probe

sequences (recommended in the CDC test procedure for MPV (9)) to the MPV reference genome

(MPV-Zaire-96-I-16). The corresponding oligo sequences with mismatches found in the genome

database for forward (MPV-F-mu) and reverse primers (MPV-R-mu) were also added on top of

the reference genome. Red nucleotides indicate the variations identified in the 683 genome

database and the nonsynonymous mutation is marketed by a red box. (**B-C**) The abundance of

MPV-F (generic) and MPV-F-mu (mutated), MPV-R (generic) and mutated (MPV-R-mu) in the

currently available 683 MPV genomes worldwide (B), and in the 58 U.S. genomes (C).

Evaluation of the specificity of other primers and probes for monkeypox virus and

orthopoxvirus detection

Next, we evaluated seven other developed real-time PCR assays, targeting *O2L* (13), *F3L* (14),

C3L, and *G2R* (10) genes for MPV, *B2R* (15), *I7L* (16) and *F8L* (17) genes for OPV detection.

The selected targets are generally conserved regions within viral genomes to maximize viral

detection (13,15). We aligned primer and probe sequences used in each of the seven assays

against the 683 MPV genomes and computed percent identity. As shown in Table 1, the four

reported assays designed for MPV detection have varied results. The primers in MPV_O2L have

a >99% match with the database, but the probe only matches 4.1% of the genomes. A perfect

match was not found for the MPV_C3L assay, which was used for the detection of the MPV

Congo Basin strain. Primers and probe sequences used in the MPV_F3L assay showed >99.4%

alignment against the genome database, suggesting its suitability for detection of the MPV-2022

outbreak. Primers used in the MPV_G2R assay designed to detect the West African strain

showed a 100% match to the database and 95.6% match for the probe thereby validating

previous phylogenetic analysis results that the current MPV lineage belongs to the West Africa

clade (20).

We further evaluated three real-time assays (OPV_B2R, OPV_I7L, and OPV_F8L) for the

detection of viruses belonging to the genus orthopoxvirus, which includes monkeypox virus,

camelpox virus, cowpox virus, and vaccinia virus (21). OPV_B2R primers highly match the

database genomes, but its probe sequence has no match (Table 1). OPV_I7L has good matches

for the forward primer and probe, but its reverse primer only matches 8.2% of the genomes.

OPV_F8L oligos for the non-variola OPV generic test recommended by CDC has a high match

percentage (>99.6%) with the genomes (Table 1). Thus, the MPV_F3L and OPV_F8L assays

have the highest match rates to the sequenced MPV genomes.

Table 1. Evaluation of the specificity of primers and probes for monkeypox virus (MPV) or orthopoxvirus (OPV) detection.

Target	Oligo	Oligo sequence (5'->3')	Percentage (Total 683)	Reference
MPV_O2L	Forward	TAGTGAGTTCGGCGACAAAG	99.7%	Wawina-Bokalanga et al.,2022
	Reverse	GTATCGCATCTCTCGGGTATTC	99.3%	
	Probe	ACCGGTAATCTTGTCGAGGAGGACA	4.1%	
MPV_F3L	Forward	CATCTATTATAGCATCAGCATCAGA	99.4%	Maksyutov et al.,2016
	Reverse	GATACTCCTCCTCGTTGGTCTAC	99.7%	
	Probe	TGTAGGCCGTGTATCAGCATCCATT	99.6%	
MPV_C3L	Forward	TGTCTACCTGGATACAGAAAGCAA	0.0%	Li et al.,2010
	Reverse	GGCATCTCCGTTTAATACATTGAT	0.0%	
	Probe	CCCATATATGCTAAATGTACCGGTACCGGA	0.0%	
MPV_G2R_WA	Forward	CACACCGTCTCTTCCACAGA	100.0%	Li et al.,2010
	Reverse	GATACAGGTTAATTTCCACATCG	100.0%	
	Probe	AACCCGTCGTAACCAGCAATACATTT	95.6%	
OPV_B2R	Forward	CTATCAAAGAGAAGGCCAA	99.9%	Stellberger et al., 2015
	Reverse	ATTCTCATAATTTCCTTTCCAT	100.0%	
	Probe	ACAATCTCCTATCCAGAGGTGGTAATC	0.0%	
OPV_I7L	Forward	TAATACTTCGATTGCTCATCCAGG	99.6%	Schroeder et al., 2010
	Reverse	ACTTCTCACAAATGGATTTGAAAATC	8.2%	
	Probe	TCCTTTACGTGATAAATCAT	99.9%	
OPV_F8L	Forward	TCAACTGAAAAGGCCATCTATGA	99.7%	CDC,2022
	Reverse	GAGTATAGAGCACTATTTCTAAATCCCA	99.7%	
	Probe	CCATGCAATATACGTACAAGATAGTAGCCAAC	99.6%	

Genetic variations across real-time PCR assays for MPV or OPV detection and

epidemiological analysis

We next investigated genomic sequences in conserved regions that differ between the real-time

PCR assays. About 96% of genomes have a G->T mutation in the probe of MPV_O2L assay,

and this mutation is present across all MPV-2022 outbreak genomes (Figure 2A). Further

analysis using the sample collection date found that this G->T mutation appeared in two samples

in 1962 and 1970, was not detected in samples from 1978 to 2007, and re-emerged from 2017

onward (Figure 2B). For the OPV_I7L assay reverse primer, a C->T mutation was observed at

the 3' end in about 92% of all genomes and in 98.7% of genomes sequenced in 2022. It is

interesting that this mutation is mostly observed in samples from Europe, South, and North

America whereas the original sequence was more common in samples from Africa and Asia

(Figure 2C). A G->C substitution in the probe sequence of OPV_B2R was observed in nearly all

genomes sequenced in the MPV-2022 outbreak (Figure 2A).

The MPV_G2R_WA assay probe has a 95.6% match to the database sequences (Figure 2A).

Two mutation types were found for the rest of 4.3% genomes. A 7-nucleotide mutation

(Mutation1) was found in 4.1% of genomes from 1978 to 2007 (Figure 2A and 2D). Mutation1

reappears in a sample obtained on June 10, 2022, from Luxembourg. Although 99.7% of the

MPV genomes are conserved in this probe region, one new C->T synonymous mutation

(Mutation2) (Figure 2A) was identified from a sample obtained on May 18, 2022 from Canada.

Those results suggest that the genetic variations on the MPV genomes corresponding with the

real-time PCR primer and probe regions could be used to indicate the temporal and spatial

emergence pattern of monkeypox disease.

Figure 2. Genetic variations across real-time PCR assays for MPV or OPV detection and epidemiological analysis. (A) Genetic variations in the MPV genome database compared to primer and probe sequences used in detection assays. **(B)** Temporal analysis for the mutation in MPV_O2L probe sequence. This mutation is found in all the genomes in 2022. **(C)** Proportions of genomes for the reverse primer used in the OPV_I7L assay with or without mutation. **(D)** MPV_G2R_WA probe sequence and its two mutation types across the genomic database. One Mutation1 sample (green dot) was found in 2022 (overshadowed by the blue dot-Mutation2).

Discussion

Accurate diagnostics are fundamental for successful epidemic control (22). PCR-based molecular methods are widely used for pathogen detection in clinical and environmental samples. As a rapid and reliable tool, TagMan real-time PCR offers high sensitivity and specificity that targets a respective pathogen's genome by using designed probe, forward and reverse primers.

Thus, the exact matches of the three oligos with the target genome are required for sensitive and

accurate diagnostics. Here, we analyzed the sequence of primers and probe used in the CDC

recommended MPV generic real-time PCR assay as well as seven other MPV or OPV testing

assays by aligning respective primer/probe sequences against published MPV full genomes. Our

results showed mismatches in more than 92% of genomes for the MPV generic forward and

reverse primers (Figure 1). One mutation C194233T is close to the 3' end of the reverse primer,

suggesting it may significantly impact the binding efficiency during amplification. Experimental

investigations are underway to quantify the impacts of those mismatches in primers on detection

sensitivity and efficiency for the new MPV lineage.

Of the seven other assays evaluated for MPV or OPV detection, MPV_F3L and OPV_F8L are

found to have the highest matches (>99.4%) to the global genome database. However, it is

necessary to mention that sequence match is one of the parameters determining the detection

sensitivity and specificity, other parameters such as primer dimer, GC content, the template DNA,

and inhibitors in the sample may also impact the diagnostic efficiency (23,24). Thus, further

experimental tests are needed to validate their amplification efficiencies and limit of detections

for the present MPV strain.

In summary, our analysis shows that primers and probe in the recommended MPV generic real-

time assay harbor wide deviations from the sequenced MPV genomes, especially the genomes

released in current monkeypox outbreak. Thus, it is critical to develop updated assays for

accurate and specific detection of MPV to inform public health risk mitigation strategies and

contain the outbreak.

Declaration of Competing Interest

The authors declare no competing interest.

Code Availability

All data and code produced in the present study are available upon reasonable request to the

authors.

Acknowledgement

This work is supported by Faculty Startup funding from the Center of Infectious Diseases at

UTHealth, the UT system Rising STARs award, and the Texas Epidemic Public Health Institute

(TEPHI) to F.W.

Reference

1. CDC. 2022 Monkeypox Outbreak Global Map [Internet]. Centers for Disease Control and
    Prevention. 2022 [cited 2022 Aug 9]. Available from:
    https://www.cdc.gov/poxvirus/monkeypox/lab-personnel/index.html

2. Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, et al.
    Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention.
    Infectious Disease Clinics. 2019 Dec 1;33(4):1027–43.

3. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic
    characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London,
    UK: a whole-genome sequencing and hospital-based cohort study. The Lancet Infectious
    Diseases. 2021 Sep 1;21(9):1246–56.

4. Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human
    monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165–82.

5. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.
    Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. New
    England Journal of Medicine. 2022 Jul 21;0(0):null.

6. Titanji BK, Tegomoh B, Nematollahi S, Konomos M, Kulkarni PA. Monkeypox: A
Contemporary Review for Healthcare Professionals. Open Forum Infectious Diseases. 2022
Jul 1;9(7):ofac310.

7. Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the
pathobiology of the monkeypox virus. Journal of Autoimmunity. 2022 Jul 1;131:102855.

8. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al. Community
transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022
Jun 2;27(22):2200422.

9. CDC. Test Procedure: Monkeypox virus Generic Real-Time PCR Test [Internet]. Centers for
Disease Control and Prevention. 2022 [cited 2022 Aug 9]. Available from:
https://www.cdc.gov/poxvirus/monkeypox/pdf/PCR-Diagnostic-Protocol-508.pdf

10. Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. Real-time PCR assays for the specific
detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods.
2010 Oct;169(1):223–7.

11. Peiró-Mestres A, Fuertes I, Camprubí-Ferrer D, Marcos MÁ, Vilella A, Navarro M, et al.
Frequent detection of monkeypox virus DNA in saliva, semen, and other clinical samples
from 12 patients, Barcelona, Spain, May to June 2022. Eurosurveillance. 2022 Jul
14;27(28):2200503.

12. Wolfe MK, Duong D, Hughes B, Chan-Herur V, White BJ, Boehm AB. Detection of
monkeypox viral DNA in a routine wastewater monitoring program [Internet]. medRxiv;
2022 [cited 2022 Aug 9]. p. 2022.07.25.22278043. Available from:
https://www.medrxiv.org/content/10.1101/2022.07.25.22278043v1

13. Wawina-Bokalanga T, Sklenovska N, Vanmechelen B, Bloemen M, Vergote V, Laenen L, et
al. An accurate and rapid Real-time PCR approach for human Monkeypox virus diagnosis
[Internet]. medRxiv; 2022 [cited 2022 Aug 9]. p. 2022.06.23.22276033. Available from:
https://www.medrxiv.org/content/10.1101/2022.06.23.22276033v1

14. Maksyutov RA, Gavrilova EV, Shchelkunov SN. Species-specific differentiation of variola,
monkeypox, and varicella-zoster viruses by multiplex real-time PCR assay. J Virol Methods.
2016 Oct;236:215–20.

15. Stellberger T, Stockmar I, Haase M, Meyer H, Zoeller G, Pavlovic M, et al. Multiplex Real-
Time PCR Assay for the Detection and Differentiation of   Poxviruses and Poxvirus
Vectors. Applied Biosafety. 2015 Dec;20(4):192–200.

16. Schroeder K, Nitsche A. Multicolour, multiplex real-time PCR assay for the detection of
human-pathogenic poxviruses. Mol Cell Probes. 2010 Apr;24(2):110–3.

17. CDC. Test Procedure: Non-variola Orthopoxvirus Generic Real-Time PCR Test [Internet].
2022. Available from: https://www.cdc.gov/poxvirus/monkeypox/pdf/non-variola-
orthopoxvirus-generic-real-time-pcr-test.pdf

18. Nasir A, Caetano-Anollés G. A phylogenomic data-driven exploration of viral origins and
evolution. Science Advances. 2015 Sep 25;1(8):e1500527.

19. Villarreal LP. Evolution of Viruses. Encyclopedia of Virology. 2008;174–84.

20. Wang L, Shang J, Weng S, Aliyari SR, Ji C, Cheng G, et al. Genomic annotation and
molecular evolution of monkeypox virus outbreak in 2022. Journal of Medical Virology
[Internet]. 2022 [cited 2022 Aug 9];1(7). Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.28036

21. Petersen BW, Karem KL, Damon IK. Orthopoxviruses: Variola, Vaccinia, Cowpox, and
Monkeypox. In: Kaslow RA, Stanberry LR, Le Duc JW, editors. Viral Infections of Humans:
Epidemiology and Control [Internet]. Boston, MA: Springer US; 2014 [cited 2022 Aug 9]. p.
501–17. Available from: https://doi.org/10.1007/978-1-4899-7448-8_21

22. Kelly-Cirino CD, Nkengasong J, Kettler H, Tongio I, Gay-Andrieu F, Escadafal C, et al.
Importance of diagnostics in epidemic and pandemic preparedness. BMJ Glob Health. 2019
Jan 29;4(Suppl 2):e001179.

23. Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJB, et al.
Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data.
Nucleic Acids Res. 2009 Apr;37(6):e45.

24. Kralik P, Ricchi M. A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions,
Parameters, and Everything. Frontiers in Microbiology [Internet]. 2017 [cited 2022 Aug
10];8. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2017.00108